Hepatitis C virus infection

Prevalence, predictor variables and prevention opportunities among drug users in Italy

Gianluca L. Quaglio, F. Lugoboni, B. Pajusco, M. Sarti, G. Talamini, P. Mezzelani, Don Des Jarlais, C. Ariano, E. Baggio, D. Banon, G. Bellio, C. Bossi, D. Cantiero, R. Casari, P. Civitelli, D. Danieli, M. Faccini, A. Fornasiero, M. A. Giacomin, E. Manzato & 8 others V. Mecenero, S. Migliozzi, A. Pani, S. Polli, M. Residori, R. Sabbion, C. Stimolo, A. Vendramin

Research output: Contribution to journalArticle

Abstract

The study assessed rates and predictor variables of hepatitis C virus (HCV) infection among drug users receiving pharmacological treatment for opiates addiction. There was a large cohort study in 16 public centres for drug users in north-eastern Italy, with data collected by standardized face-to-face interviews between February 2001 and August 2001. Of 1095 participants, 74.2% were HCV seropositive. Anti-HCV status was independently associated with duration of drug use of over 10 years, injecting as a route of drug administration, and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) seropositivity. Further statistical analysis was conducted by dividing the subjects on the basis of the duration of heroin use: more or <10 years. In the multivariate analyses, route of drug administration and HBV status were associated with HCV seropositivity among both groups. Less education was associated with HCV among the shorter term drug users. HIV status and having a sexual partner with a history of drug use were associated with HCV seropositivity among the longer term drug users. Half of the short-term heroin users were still HCV seronegative when starting treatment, suggesting opportunities for reducing new HCV infections. Remarkable was the relationship between vaccination for hepatitis B and HCV serostatus. Being HBV seropositive was strongly associated with being HCV seropositive. But heroin users who had been vaccinated for HBV were not significantly more likely to be HCV seropositive than heroin users who were HBV seronegative. HBV vaccination does not provide biological protection against HCV; however, vaccinating heroin users against HBV may help to create a stronger pro-health attitude among heroin users, leading to a reduction in HCV risk behaviour.

Original languageEnglish (US)
Pages (from-to)394-400
Number of pages7
JournalJournal of Viral Hepatitis
Volume10
Issue number5
DOIs
StatePublished - Sep 1 2003

Fingerprint

Virus Diseases
Drug Users
Hepacivirus
Italy
Hepatitis B virus
Heroin
Drug Administration Routes
Vaccination
HIV
Opioid-Related Disorders
Attitude to Health
Sexual Partners
Risk-Taking
Hepatitis B
Pharmaceutical Preparations
Cohort Studies
Multivariate Analysis
Pharmacology
Interviews

Keywords

  • Drug users
  • Hepatitis C virus
  • Predictor variables
  • Prevalence
  • Prevention opportunities

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Quaglio, G. L., Lugoboni, F., Pajusco, B., Sarti, M., Talamini, G., Mezzelani, P., ... Vendramin, A. (2003). Hepatitis C virus infection: Prevalence, predictor variables and prevention opportunities among drug users in Italy. Journal of Viral Hepatitis, 10(5), 394-400. https://doi.org/10.1046/j.1365-2893.2003.00448.x

Hepatitis C virus infection : Prevalence, predictor variables and prevention opportunities among drug users in Italy. / Quaglio, Gianluca L.; Lugoboni, F.; Pajusco, B.; Sarti, M.; Talamini, G.; Mezzelani, P.; Des Jarlais, Don; Ariano, C.; Baggio, E.; Banon, D.; Bellio, G.; Bossi, C.; Cantiero, D.; Casari, R.; Civitelli, P.; Danieli, D.; Faccini, M.; Fornasiero, A.; Giacomin, M. A.; Manzato, E.; Mecenero, V.; Migliozzi, S.; Pani, A.; Polli, S.; Residori, M.; Sabbion, R.; Stimolo, C.; Vendramin, A.

In: Journal of Viral Hepatitis, Vol. 10, No. 5, 01.09.2003, p. 394-400.

Research output: Contribution to journalArticle

Quaglio, GL, Lugoboni, F, Pajusco, B, Sarti, M, Talamini, G, Mezzelani, P, Des Jarlais, D, Ariano, C, Baggio, E, Banon, D, Bellio, G, Bossi, C, Cantiero, D, Casari, R, Civitelli, P, Danieli, D, Faccini, M, Fornasiero, A, Giacomin, MA, Manzato, E, Mecenero, V, Migliozzi, S, Pani, A, Polli, S, Residori, M, Sabbion, R, Stimolo, C & Vendramin, A 2003, 'Hepatitis C virus infection: Prevalence, predictor variables and prevention opportunities among drug users in Italy', Journal of Viral Hepatitis, vol. 10, no. 5, pp. 394-400. https://doi.org/10.1046/j.1365-2893.2003.00448.x
Quaglio, Gianluca L. ; Lugoboni, F. ; Pajusco, B. ; Sarti, M. ; Talamini, G. ; Mezzelani, P. ; Des Jarlais, Don ; Ariano, C. ; Baggio, E. ; Banon, D. ; Bellio, G. ; Bossi, C. ; Cantiero, D. ; Casari, R. ; Civitelli, P. ; Danieli, D. ; Faccini, M. ; Fornasiero, A. ; Giacomin, M. A. ; Manzato, E. ; Mecenero, V. ; Migliozzi, S. ; Pani, A. ; Polli, S. ; Residori, M. ; Sabbion, R. ; Stimolo, C. ; Vendramin, A. / Hepatitis C virus infection : Prevalence, predictor variables and prevention opportunities among drug users in Italy. In: Journal of Viral Hepatitis. 2003 ; Vol. 10, No. 5. pp. 394-400.
@article{362539af9d834621b5dbeb64f2004f66,
title = "Hepatitis C virus infection: Prevalence, predictor variables and prevention opportunities among drug users in Italy",
abstract = "The study assessed rates and predictor variables of hepatitis C virus (HCV) infection among drug users receiving pharmacological treatment for opiates addiction. There was a large cohort study in 16 public centres for drug users in north-eastern Italy, with data collected by standardized face-to-face interviews between February 2001 and August 2001. Of 1095 participants, 74.2{\%} were HCV seropositive. Anti-HCV status was independently associated with duration of drug use of over 10 years, injecting as a route of drug administration, and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) seropositivity. Further statistical analysis was conducted by dividing the subjects on the basis of the duration of heroin use: more or <10 years. In the multivariate analyses, route of drug administration and HBV status were associated with HCV seropositivity among both groups. Less education was associated with HCV among the shorter term drug users. HIV status and having a sexual partner with a history of drug use were associated with HCV seropositivity among the longer term drug users. Half of the short-term heroin users were still HCV seronegative when starting treatment, suggesting opportunities for reducing new HCV infections. Remarkable was the relationship between vaccination for hepatitis B and HCV serostatus. Being HBV seropositive was strongly associated with being HCV seropositive. But heroin users who had been vaccinated for HBV were not significantly more likely to be HCV seropositive than heroin users who were HBV seronegative. HBV vaccination does not provide biological protection against HCV; however, vaccinating heroin users against HBV may help to create a stronger pro-health attitude among heroin users, leading to a reduction in HCV risk behaviour.",
keywords = "Drug users, Hepatitis C virus, Predictor variables, Prevalence, Prevention opportunities",
author = "Quaglio, {Gianluca L.} and F. Lugoboni and B. Pajusco and M. Sarti and G. Talamini and P. Mezzelani and {Des Jarlais}, Don and C. Ariano and E. Baggio and D. Banon and G. Bellio and C. Bossi and D. Cantiero and R. Casari and P. Civitelli and D. Danieli and M. Faccini and A. Fornasiero and Giacomin, {M. A.} and E. Manzato and V. Mecenero and S. Migliozzi and A. Pani and S. Polli and M. Residori and R. Sabbion and C. Stimolo and A. Vendramin",
year = "2003",
month = "9",
day = "1",
doi = "10.1046/j.1365-2893.2003.00448.x",
language = "English (US)",
volume = "10",
pages = "394--400",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Hepatitis C virus infection

T2 - Prevalence, predictor variables and prevention opportunities among drug users in Italy

AU - Quaglio, Gianluca L.

AU - Lugoboni, F.

AU - Pajusco, B.

AU - Sarti, M.

AU - Talamini, G.

AU - Mezzelani, P.

AU - Des Jarlais, Don

AU - Ariano, C.

AU - Baggio, E.

AU - Banon, D.

AU - Bellio, G.

AU - Bossi, C.

AU - Cantiero, D.

AU - Casari, R.

AU - Civitelli, P.

AU - Danieli, D.

AU - Faccini, M.

AU - Fornasiero, A.

AU - Giacomin, M. A.

AU - Manzato, E.

AU - Mecenero, V.

AU - Migliozzi, S.

AU - Pani, A.

AU - Polli, S.

AU - Residori, M.

AU - Sabbion, R.

AU - Stimolo, C.

AU - Vendramin, A.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The study assessed rates and predictor variables of hepatitis C virus (HCV) infection among drug users receiving pharmacological treatment for opiates addiction. There was a large cohort study in 16 public centres for drug users in north-eastern Italy, with data collected by standardized face-to-face interviews between February 2001 and August 2001. Of 1095 participants, 74.2% were HCV seropositive. Anti-HCV status was independently associated with duration of drug use of over 10 years, injecting as a route of drug administration, and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) seropositivity. Further statistical analysis was conducted by dividing the subjects on the basis of the duration of heroin use: more or <10 years. In the multivariate analyses, route of drug administration and HBV status were associated with HCV seropositivity among both groups. Less education was associated with HCV among the shorter term drug users. HIV status and having a sexual partner with a history of drug use were associated with HCV seropositivity among the longer term drug users. Half of the short-term heroin users were still HCV seronegative when starting treatment, suggesting opportunities for reducing new HCV infections. Remarkable was the relationship between vaccination for hepatitis B and HCV serostatus. Being HBV seropositive was strongly associated with being HCV seropositive. But heroin users who had been vaccinated for HBV were not significantly more likely to be HCV seropositive than heroin users who were HBV seronegative. HBV vaccination does not provide biological protection against HCV; however, vaccinating heroin users against HBV may help to create a stronger pro-health attitude among heroin users, leading to a reduction in HCV risk behaviour.

AB - The study assessed rates and predictor variables of hepatitis C virus (HCV) infection among drug users receiving pharmacological treatment for opiates addiction. There was a large cohort study in 16 public centres for drug users in north-eastern Italy, with data collected by standardized face-to-face interviews between February 2001 and August 2001. Of 1095 participants, 74.2% were HCV seropositive. Anti-HCV status was independently associated with duration of drug use of over 10 years, injecting as a route of drug administration, and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) seropositivity. Further statistical analysis was conducted by dividing the subjects on the basis of the duration of heroin use: more or <10 years. In the multivariate analyses, route of drug administration and HBV status were associated with HCV seropositivity among both groups. Less education was associated with HCV among the shorter term drug users. HIV status and having a sexual partner with a history of drug use were associated with HCV seropositivity among the longer term drug users. Half of the short-term heroin users were still HCV seronegative when starting treatment, suggesting opportunities for reducing new HCV infections. Remarkable was the relationship between vaccination for hepatitis B and HCV serostatus. Being HBV seropositive was strongly associated with being HCV seropositive. But heroin users who had been vaccinated for HBV were not significantly more likely to be HCV seropositive than heroin users who were HBV seronegative. HBV vaccination does not provide biological protection against HCV; however, vaccinating heroin users against HBV may help to create a stronger pro-health attitude among heroin users, leading to a reduction in HCV risk behaviour.

KW - Drug users

KW - Hepatitis C virus

KW - Predictor variables

KW - Prevalence

KW - Prevention opportunities

UR - http://www.scopus.com/inward/record.url?scp=10744224714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224714&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2893.2003.00448.x

DO - 10.1046/j.1365-2893.2003.00448.x

M3 - Article

VL - 10

SP - 394

EP - 400

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 5

ER -